Education and Awareness Program Targeting the Assessment of Adherence of the Treatment of Dyslipidemia (PRECAVER)

Primary Care Clinic

Inclusion Criteria:

• Subjects eligible for the treatment of dyslipidemia with statins according the current guidelines NCEP ATPIII and IV Brazilian Guidelines of Dyslipidemia and Atherosclerosis Prevention.
• Patients with previous use of rosuvastatin for, at least, 15 days and, for no longer than12 months prior to the inclusion in the study.

Exclusion Criteria:

Pregnancy and childbearing

• History of severe hypersensitivity (including myopathy) to other HMG-CoA reductase inhibitors.
• Subjects with indication of use of cyclosporine and other associations of other lipid lowering drugs.
• Subjects with underlying diseases that may influence lipid levels (i.e. uncontrolled hypothyroidism defined as a Thyroid stimulating hormone (TSH) > 1.5 times upper level of normality (ULN) at Visit 1, AIDS, transplanted subjects, etc).
• History of drug and alcohol abuse.
• Current active liver disease or hepatic failure or elevations in ALT >3 times the ULN.
• Elevation of CPK > 3 times the ULN.
• Elevation in the seric creatinine > 2,0 mg / dL.
• History of malignancy in the last 5 years, except basal cell or squamous cell carcinoma of the skin (women with a history of Cervical dysplasia must be included, unless they have t3 clear consecutive Papanicolaou (Pap) smears , before the entry in the study).
• Any other known clinical condition that, in the opinion of the investigator, may compromise the subject's safety.